CORT vs TEVA: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of September 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: TEVA is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CORT and TEVA share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CORT and TEVA exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Corcept Therapeutics is a commercial-stage pharmaceutical company focused on disorders driven by excess cortisol activity. Its foundation is Korlym (mifepristone), a glucocorticoid receptor modulator approved for hypercortisolism (Cushing's syndrome), which generated the bulk of its ~$761 million in 2025 revenue. The company has spent years building physician awareness that hypercortisolism is more common than historically recognized, driving record new-patient starts, and it is expanding beyond a single product: the FDA approved Lifyorli (relacorilant) for platinum-resistant ovarian cancer in March 2026, and Corcept resubmitted a New Drug Application for relacorilant in Cushing's syndrome in June 2026.

Full CORT guide

Teva Pharmaceutical Industries is a global pharmaceutical company and one of the largest generic-drug manufacturers in the world, headquartered in Israel and listed in the US as an ADR. Its business has two broad pillars: a large, mature generics and biosimilars operation that supplies affordable versions of off-patent medicines across many markets, and a growing innovative (branded specialty) portfolio concentrated in neuroscience and respiratory conditions. Key branded products include AUSTEDO for movement disorders such as tardive dyskinesia and Huntington's chorea, UZEDY, a long-acting injectable for schizophrenia, and AJOVY for migraine prevention. Teva also runs an active pharmaceutical ingredients business and a biosimilars program targeting hundreds of millions in revenue by 2027.

Full TEVA guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CORT drivers: Cushing's / hypercortisolism growth runway; Relacorilant as the next-generation successor.
• TEVA drivers: Innovative neuroscience growth engine; Pivot to Growth and deleveraging.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Revenue concentration is the defining risk: Korlym still drives the overwhelming majority of sales, and a court ruling has cleared a path for Teva's generic mifepristone, which could erode the flagship franchise faster than the new products scale. For TEVA, teva carries meaningful risks despite the improving story.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CORT if you believe its drivers more; TEVA if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CORT and TEVA guides.

CORT. Corcept is profitable on a full-year basis but posted a Q1 2026 net loss of roughly $32 million as it ramped Lifyorli launch spending (SG&A near $145 million, R&D near $66 million). The trailing P/E near 50x reflects a growth-and-optionality premium rather than a value multiple. The zero-debt balance sheet and half-billion-dollar cash cushion give it flexibility to fund launches and litigation internally.

TEVA. These figures are approximate, qualitative, and tied to the asOf date; verify live numbers before acting. Teva trades largely on the credibility of its turnaround, so the market weighs innovative-product momentum and debt reduction more than any single quarter's headline number. Because reported (GAAP) results can be distorted by litigation charges, impairments, and amortization, investors often focus on adjusted metrics; compare both, and confirm current leverage and guidance directly from company filings.

Headline figures (approximate, July 2026): CORT shows revenue (ttm) ~$770M, fy2025 revenue ~$761M, fy2026 revenue guidance ~$950M to $1.05B, market cap ~$9.4B; TEVA shows quarterly revenue (q1 2026) Roughly $4 billion, ahead of expectations, adjusted (non-gaap) eps (q1 2026) Modest and up low-single-digits year over year, beating consensus, innovative portfolio growth Strong, up roughly 40% year over year, led by AUSTEDO, profitability targets Management targets around a 30% operating margin under Pivot to Growth.

CORT and TEVA are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CORT and TEVA exposure against your real portfolio. It is not an investment adviser.